newsfilter
← Latest News
Business Wire·

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster